Maze Therapeutics, Inc.
Maze Therapeutics, Inc. (MAZE): 3 pipeline candidates · ~27 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
27.1 months
D/E 0.23 · 8% dilution
Lead: Phase 2
3 candidates
N/A
0 buys · 54 sells (180d)
A transparent, data-derived signal for Maze Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.3B
Cash
$199.9M
Quarterly Burn
$39.1M
Runway
27.1 mo
Revenue
$20.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
164
Total value held
$1.24B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 5,717,752 | $170.6M |
| arch venture management, llc | 4,120,053 | $123.0M |
| deep track capital, lp | 3,477,562 | $103.8M |
| vanguard capital management llc | 2,871,312 | $85.7M |
| blackrock, inc. | 2,570,425 | $76.7M |
| alphabet inc. | 1,388,583 | $41.4M |
| woodline partners lp | 1,300,458 | $38.8M |
| logos global management lp | 1,235,000 | $36.9M |
| adage capital partners gp, l.l.c. | 1,178,000 | $35.2M |
| general catalyst group management, llc | 1,035,910 | $30.9M |
Showing top 10 of 164 institutional holders of Maze Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Maze Therapeutics, Inc.'s pipeline?
Maze Therapeutics, Inc. (MAZE) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Maze Therapeutics, Inc.'s lead drug candidate?
Maze Therapeutics, Inc.'s most advanced tracked candidate is mze001 (Phase 1) for Pompe disease.
What is Maze Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Maze Therapeutics, Inc. has approximately 27.1 months of cash runway.
What is Maze Therapeutics, Inc.'s market capitalization?
Maze Therapeutics, Inc.'s market capitalization is approximately $1.3B.
Who is the CEO of Maze Therapeutics, Inc.?
Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. is the chief executive officer of Maze Therapeutics, Inc. (MAZE).
Get the full picture on Maze Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.